Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 91Leukemia, Lymphocytic, Chronic, B-Cell 28Myelodysplastic Syndromes 18Recurrence 9Lymphoma, Mantle-Cell 9Leukemia, Biphenotypic, Acute 8Burkitt Lymphoma 8Waldenstrom Macroglobulinemia 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myelomonocytic, Chronic 7Leukemia 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Neoplasms 6Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma 6Hematologic Neoplasms 6Lymphoma, Follicular 4Myeloproliferative Disorders 3Multiple Myeloma 3Anemia, Refractory, with Excess of Blasts 3Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, B-Cell 2Leukemia, Myeloid 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Blast Crisis 2Venentoclax 1Targeted Therapy 1Sarcoma, Myeloid 1

Interventions

ruxolitinib 9fludarabine phosphate 8fludarabine 8Whole-Body Irradiation 8Specimen Handling 7Cytarabine 7Cyclophosphamide 7Mycophenolic Acid 6Tacrolimus 5Injections 5Busulfan 5Biopsy 5Azacitidine 5Stem Cell Transplantation 4Sirolimus 4Peripheral Blood Stem Cell Transplantation 4Melphalan 4Granulocyte Colony-Stimulating Factor 4CPX-351 4venetoclax 3luspatercept 3decitabine and cedazuridine drug combination 3Liposomes 3Idarubicin 3Daunorubicin 3Cyclosporine 3Blood Specimen Collection 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3selinexor 2nilotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × venetoclax × 90 days × Clear all
NCT05554406 2026-06-05

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
335 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡